Why the study?
Is mitral valve surgery feasible and effective for mitral regurgitation caused by Libman-Sacks endocarditis?
Is mitral valve surgery feasible and effective for mitral regurgitation caused by Libman-Sacks endocarditis?
Mitral valve repair is a feasible and effective surgical option for young patients with stable SLE/APS and localized Libman-Sacks endocarditis.
Answers are grounded in this paper and cite their sources.
Supports mitral valve repair in selected young patients with stable SLE/APS; extends evidence for Libman-Sacks endocarditis beyond case reports.
Libman-Sacks endocarditis of the mitral valve was first described by Libman and Sacks in 1924. Currently, the sterile verrucous vegetative lesions seen in Libman-Sacks endocarditis are regarded as a cardiac manifestation of both systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS). Although typically mild and asymptomatic, complications of Libman-Sacks endocarditis may include superimposed bacterial endocarditis, thromboembolic events, and severe valvular regurgitation and/or stenosis requiring surgery. In this study we report two cases of mitral valve repair and two cases of mitral valve replacement for mitral regurgitation (MR) caused by Libman-Sacks endocarditis. In addition, we provide a systematic review of the English literature on mitral valve surgery for MR caused by Libman-Sacks endocarditis. This report shows that mitral valve repair is feasible and effective in young patients with relatively stable SLE and/or APS and only localized mitral valve abnormalities caused by Libman-Sacks endocarditis. Both clinical and echocardiographic follow-up after repair show excellent mid- and long-term results.
No takes yet. Share an insight, caveat, or question.
Bouma et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: